Business Wire

Zanoprima Launches Commercial Production of Its High Purity Tobacco-Free Synthetic (S) Nicotine Using Revolutionary Patented New Process

Share

Zanoprima Lifesciences (www.zanoprima.com) (https://www.linkedin.com/company/zanoprima/) a UK based company, announced commercial production of its high purity synthetic (S)-Nicotine (SyNic) using a revolutionary patented process that does not involve the use of tobacco or any synthetic racemic mixture.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005296/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Zanoprima's tobacco-free high purity synthetic (S) Nicotine is SyNic (Graphic: Business Wire)

This is a landmark development for the trillion-dollar tobacco industry and its 1.3 billion consumers as it heralds the arrival of a superior, substantially lower-risk, cost-effective, and greener alternative to a global industry that is arguably the single biggest avoidable cause of death globally.

Zanoprima has developed and patented the process to manufacture high purity (typically 99.9%), synthetic (S)-Nicotine (SyNic) for commercial use that is free of TSNA (tobacco-specific Nitrosamines), toxins, carcinogens, odour, and harsh taste. Zanoprima offers the entire range of products including SyNic (S)-Nicotine Bitartrate (Nicotine Bitartrate Dihydrate), SyNic (S)-Nicotine polacrilex resin/Nicotine resinate and its novel proprietary (S)-Nicotine complex.

SyNic (S)-Nicotine conforms to and exceeds European Pharmacopeia (EP) and United States Pharmacopeia (USP) specifications. “Green Chemistry” principles compliant production process minimizes the environmental impacts of nicotine production. Applications include:

SyNic Protonated (S)-Nicotine e-liquid for e-cigarettes is without any potentially harmful ingredients such as organic acids and propylene glycol. It is pure, stable and has a long shelf life. E-cigarettes that use SyNic offer a smooth taste and enhanced nicotine experience, a distinct advantage given the nicotine limit guidelines/rules in e-liquids in the EU and other geographies.

Znus: Tobacco-free white snus is completely sodium and tobacco free, delivering a smooth taste without the characteristic odour and harshness of natural nicotine. It has an instant burst followed by sustained release as desired by the traditional Snus users.

Next-gen chewing gum and lozenges that are sodium free offer unique characteristics, providing an instant burst and sustained release of nicotine that users seek. These gums and lozenges contain a new proprietary nicotine complex with superior bioavailability and taste.

Forthcoming launches: Tobacco free heated nicotine products unlike existing tobacco-based Heat Not Burn products and skin friendly transdermal patches for Alzheimer’s and dementia.

Global Patents: Zanoprima owns patent applications or registration for its revolutionary manufacturing process in all major geographies including United States, Europe, Great Britain, Australia, China, India, and others.

As a responsible synthetic nicotine (SyNic) manufacturer Zanoprima will distribute SyNic in strict compliance with regulations in each of its markets, globally.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ashok Narasimhan
Zanoprima Lifesciences
ashok@zanoprima.com
+44-20-8863 1303

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member10.5.2024 18:45:00 EEST | Press release

EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Pejvack Motlagh MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. “We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience. The appointment of Dr Motlagh is critical for Egle, as the company is moving to clinical development of assets in oncology and auto-immunity. Pejvack will impact the future development of the rich pipeline at Egle, based on the modulation of regulatory T cells. As we advance toward the clinical development of EGL-001, John’s expertise in business development in the field of oncology is instrumental for us to successfully execute on our strategic priorities.” said Vincent Brichard, M.D., EGLE’s Interim CEO and Board member. “I am excited to join Egle Therapeutics to translate into the c

HighRadius Named 2024 Gartner® Magic Quadrant™ Leader for the Third Time in a Row10.5.2024 17:00:00 EEST | Press release

HighRadius, the leading provider of the Autonomous Finance Platform for the office of the CFO, has once again been named a Leader in the 2024 Gartner Magic Quadrant for Invoice-to-Cash Applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240510668572/en/ HighRadius Named 2024 Gartner® Magic Quadrant™ Leader for the Third Time in a Row (Graphic: Business Wire) Gartner Magic Quadrant gives enterprise technology shoppers an unbiased assessment of how well-competing providers are performing against Gartner’s market view and is supplemented by validated user reviews. According to Gartner, “Leaders execute well against their current vision and are well positioned for tomorrow.” This is the third consecutive year for HighRadius to be placed as a leader on the report. “We're honored to be recognized for our maniacal focus on invoice-to-cash business outcome improvements - DSO, Bad Debt, Interchange Fees, & Productivity,” sai

The Ministry of Investment of Saudi Arabia (MISA) Signs MoU with Ant International to Expand Business in Saudi Arabia, Supporting Regional Digital Innovation10.5.2024 16:36:00 EEST | Press release

The Ministry of Investment of Saudi Arabia (MISA) has signed a Memorandum of Understanding (MoU) with Ant International, to facilitate the business expansion into the Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507130337/en/ (Photo: Business Wire) Ant International’s President, Douglas Feagin, met with Mr. Eng Saleh Khabti, Deputy Minister of Investment of Saudi Arabia during a signing ceremony held in Riyadh, to welcome the new partnership and sign an agreement outlining shared goals for technological innovation and economic growth opportunities in Saudi Arabia. Through this partnership, MISA welcomes and supports Ant International’s expansion plan to establish an entity in Saudi Arabia, enabling assistance when acquiring licences and certificates to expand and enhance its service offerings. Ant International will use Saudi Arabia as a key gateway into the Middle East to further expand the reach of its paymen

Wipro Appoints Vinay Firake as Chief Executive Officer for APMEA Strategic Market Unit10.5.2024 16:11:00 EEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Vinay Firake as the Chief Executive Officer, APMEA (Asia Pacific, India, Middle East & Africa) Strategic Market Unit (SMU), effective immediately. Vinay will report to Srini Pallia and will also join the Wipro Executive Board. Vinay has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Senior Vice President and Managing Director of Wipro-Nordics Business Unit based in Stockholm, where he led Operations across all industries and services. Prior to that, he led the Manufacturing & Automotive Business Unit in Europe and held various roles spanning Europe and North America, including Global Head for the Enterprise Digital Operations & Platforms business and Sales Head for Wipro's Enterprise Applications businesses in Europe. “Vinay has successfully led Wipro in diverse regio

Kolmar BNH, a Top-Tier Korean Enterprise Specializing in the Production of HemoHIM, Dedicates over 2% of its Annual Sales to R&D10.5.2024 16:00:00 EEST | Press release

Kolmar BNH (KOSDAQ: 200130), a manufacturer of HemoHIM, a health-enhancing functional food, has emerged as a frontrunner in the global Original Development Manufacturing (ODM) market, owing to its pioneering investments in research and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240510895890/en/ A researcher from Kolmar BNH Health Food Lab. (Photo: Kolmar BNH) Founded in 2005, Kolmar BNH is an ODM company for health-functional food products. ODM enterprises, encompassing various sectors from trend analysis to R&D, product conceptualization, manufacturing, and quality assurance, cater to customers with entrepreneurial aspirations. This framework facilitates opportunities for individuals with a passion for business and ideas. The cornerstone of Kolmar BNH's competitiveness lies in its technological adeptness, underpinned by substantial R&D investments. The company annually allocates over 2% of its sales revenue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye